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SUMMARY
Purpose: It is unclear why some children with falciparum
malaria develop acute seizures and what determines the
phenotype of seizures. We sought to determine if poly-
morphisms of malaria candidate genes are associated
with acute seizures.
Methods: Logistic regression was used to investigate
genetic associations with malaria-associated seizures
(MAS) and complex MAS (repetitive, prolonged, or focal
seizures) in four MalariaGEN African sites, namely: Blan-
tyre, Malawi; Kilifi, Kenya; Kumasi, Ghana; and Muheza,
Tanzania. The analysis was repeated for five inheritance
models (dominant, heterozygous, recessive, additive, and
general) and adjusted for potential confounders and mul-
tiple testing.
Key Findings: Complex phenotypes of seizures consti-
tuted 71% of all admissions with MAS across the sites.
MAS were strongly associated with cluster of differentia-
tion-ligand-rs3092945 in females in Kilifi (p = 0.00068)
and interleukin (IL)-17 receptor E-rs708567 in the pooled
analysis across the sites (p = 0.00709). Complex MAS
were strongly associated with epidermal growth factor
module-containing mucin-like hormone receptor (EMR)
1-rs373533 in Kumasi (p = 0.00033), but none in the
pooled analysis. Focal MAS were strongly associated with
IL-20 receptor A-rs1555498 in Muheza (p = 0.00016), but
none in the pooled analysis. ProlongedMASwere strongly
associated with complement receptor 1-rs17047660 in
Kilifi (p = 0.00121) and glucose-6-phosphate dehydroge-
nase-rs1050828 in females in the pooled analysis
(p = 0.00155). Repetitive MAS were strongly associated
with EMR1-rs373533 in Kumasi (p = 0.00003) and cystic
fibrosis transmembrane conductance receptor-
rs17140229 in the pooled analysis (p = 0.00543). MAS
with coma/cerebral malaria were strongly associated with
EMR1-rs373533 in Kumasi (p = 0.00019) and IL10-
rs3024500 in the pooled analysis across the sites
(p = 0.00064).
Significance: We have identified a number of genetic
associations that may explain the risk of seizures in >2,000
cases admitted to hospitals with MAS across four sites in
Africa. These associations differed according to pheno-
type of seizures and site.
KEY WORDS: Africa, Children, Seizure phenotypes,
Malaria-associated seizures, Genetic risk.
Acute seizures are common in children admitted with
falciparum malaria to hospitals in sub-Saharan Africa
(Taylor et al., 2006; Idro et al., 2008). Some malarial
seizures are focal, repetitive, or prolonged (complex),
which are associated with the development of subsequent
neurocognitive impairments or epilepsy (Carter et al.,
2005; Birbeck et al., 2010). It is not clear if these sei-
zures are febrile seizures or acute symptomatic seizures
caused by the sequestration of the parasites within the
brain (Idro et al., 2005). Furthermore, it is difficult to
attribute seizures to malaria in a malaria-endemic area,
since a proportion of children will have sequestered para-
sites and be asymptomatic, and malaria is the most com-
mon cause of fever in children aged 6 months to 6 years
(Idro et al., 2005). We have determined that most
seizures in children admitted to hospital with malaria par-
asitemia are attributable to malaria using logistic regres-
sion techniques (Kariuki et al., 2011), and that children
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admitted with seizures are more likely to have relatives
with seizure disorders than controls (Versteeg et al.,
2003).
There is a strong genetic predisposition for febrile sei-
zures, investigated through twin studies, family history, and
a number of genetic polymorphisms (DNA sequence varia-
tion occurring when a single nucleotide—A, T, C, or G—n
the genome differs between members of a biologic species;
Rich et al., 1987; Kugler & Johnson, 1998; Kjeldsen et al.,
2002). The risk of febrile seizures has been associated with
interleukin-1b (IL-1B; Virta et al., 2002; Kira et al., 2005)
and interleukin-1 receptor antagonist (IL-1RA; Tsai, 1987).
Furthermore, a number of polymorphisms associated with
falciparum malaria infections have been identified, which
may be protective for example, sickle cell trait (Williams
et al., 2005), glucose-6-phosphate dehydrogenase (G6PD;
Clark et al., 2009), interadhesion molecule (ICAM-1;
Kun et al., 1999), and cluster of differentiation ligand
(CD-40LG; Sabeti et al., 2002), or susceptible, for example,
complement receptor (CR-1; Nagayasu et al., 2001) and
IL-10, -12, and -18 (Chaisavaneeyakorn et al., 2003; Wil-
son et al., 2005). However, the role of these genes in the
genesis of seizures has not been examined.
We examined a number of different polymorphisms asso-
ciated with malaria-associated seizures (MAS), and the phe-
notypes of MAS using 4,472 children admitted to hospitals
with falciparum malaria in four African countries (Ghana,
Kenya, Malawi, and Tanzania) as part of a case–control
study for MalariaGEN (Malaria Genetic Epidemiological
Network) consortial project (MalariaGEN, 2008). The
malaria candidate polymorphisms in the MalariaGEN con-
sortial project (Table S1) were chosen for this analysis
because they reflect a pathogenic mechanism for severe
malaria that could be involved in the genesis of acute sei-
zures in falciparummalaria. Malaria pathogenesis is consid-
ered in the context of malaria with impaired consciousness
and/or respiratory distress (Marsh et al., 1996), although the
former (of which cerebral malaria is the most important
severe neurologic complication) is important as seizures
occur in >80% of the cases (Idro et al., 2005).
Methods
Study sites, participants, and samples
The study participants for this analysis were recruited
from four of the sites contributing date to the MalariaGEN
study as described in detail elsewhere (MalariaGEN, 2008).
The four sites were Queen Elizabeth Central Hospital, Blan-
tyre, Malawi; Kilifi District Hospital on the coast of Kenya;
Teule Hospital in Moshi, Tanzania; and Komfo Anokye
Teaching Hospital in Kumasi, Ghana.
The entomologic inoculation rate (EIR) for P. falcipa-
rum in the city of Blantyre is estimated to be around one
infective bite/person/year, but a high proportion of families
make regular visits to nearby rural areas where the EIR is
estimated to be >100 (Table S2). In Kilifi, the overall
annual EIR has been estimated at 1–100, and recent years
have seen a significant decline in the rate of transmission
from mesoendemic in the 1990s to hypoendemic transmis-
sion today. In Kumasi, Annual Biting Rates and Annual
Entomological Inoculation Rates have been reported to be
11,643 and 866, respectively. Muheza has an intense trans-
mission of P. falciparum (50–700 infected bites/person/
year), with two seasonal peaks and the community pre-
valence of P. falciparum in children aged 2–5 years in the
study area recorded as high as 88.2% in 2002. Additional
detailed description of the sites is provided in Table S2.
Detailed data were available for each study participant,
including a range of demographic parameters. We defined
cases as children admitted to hospital with severe malaria
with a history of seizures during the acute illness, and con-
trols as children admitted with severe malaria without a
history of seizures during their life. Severe malaria was
diagnosed as the presence of peripheral parasitemia in the
blood of a child presenting with coma or impaired con-
sciousness, respiratory distress, acidosis (base excess less
than 8), hypoglycemia (whole blood glucose < 2.2 mM),
and/or severe normocytic anemia (<5 g/dl), with exclusion
of other coincidental causes of severe illnesses such as
pneumonia (Marsh et al., 1995; World Health Organization,
2000). The blood was put on a slide stained with 10%
Giemsa. The distribution of cases and controls, in that order,
was 770 and 620 in Blantyre, 900 and 1,148 in Kilifi, 250
and 250 in Kumasi, and 175 and 359 in Muheza. Children in
this study were treated appropriately according to the local
national guidelines and protocols.
Case definitions of phenotypes of MAS
Children with MAS (whose DNA samples were available
for genotyping) admitted to hospital between 1996 and
2001 in Blantyre, 2002 and 2008 in Kilifi, 2006 and 2009 in
Kumasi, and 2006 and 2007 in Muheza were selected.
Details about various seizure semiologies and or malaria
were extracted from the clinical notes and databases at each
site, and the notes were further examined in order to catego-
rize cases and controls.
We classified MAS into two major phenotypes namely:
simple and complex, with complex further subdivided into
focal MAS, repetitive MAS, and prolonged MAS (Table 1),
based upon the International League Against Epilepsy defi-
nitions for acute/febrile seizures (ILAE, 1989, 1993). Focal
MAS were defined as convulsions, twitches, or subtle sei-
zures (cycling or suckling movements) starting in one part
of the body or associated with lateralized asymmetric body
weakness (Todd’s paresis). Repetitive seizures were defined
as two or more seizures occurring within 24 h of an illness
or during the same illness. Seizures occurring in the ward
were considered prolonged if they were lasting  15 min as
documented by a clinician or a nurse, or phenytoin or phe-
nobarbital was needed to stop uncontrolled seizures, or if
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seizures on admission did not stop after the first dose of
diazepam (Sadarangani et al., 2008). Seizures were also
considered prolonged if the histories from parents or care-
takers, who rarely have watches, suggested that they lasted
for  15 min, that is, seizures lasting the period of the jour-
ney to the hospital for those living more than a kilometer
away, or seizures lasting more than the period of boiling a
pot of maize, milking a dairy cow, or lasting more than the
news broadcast on the radio. The “all focal,” “all repetitive”
or “all prolonged” included any complex phenotype and
were not mutually exclusive (Gwer et al., 2012). Simple
seizures included those that were short (<15 min or if paren-
tal history as explained above suggested so), generalized
and occurred once during the episode of malaria.
MAS in cerebral malaria (defined as impaired conscious-
ness [Blantyre Coma Score  2] in a child with peripheral
malaria parasitemia in whom other causes of encephalopa-
thy such as hypoglycemia and bacterial meningitis were
excluded) are in this study referred to as “MAS with coma”
because the occurrence of prolonged seizures may have con-
tributed to the depressed conscious level in some children.
The genetic associations with MAS were investigated for
six phenotypes, namely, all MAS, all focal MAS, all pro-
longed MAS, all repetitive MAS, all complex MAS, and all
MAS with coma. In addition to being common in malaria,
complex MAS are thought by some authors to form a more
homogeneous group for genetic studies (Baulac et al., 2004).
Genetic data
Venous blood collected at admission from study subjects
was separated by centrifugation, and the packed cells were
stored at80°C prior to subsequent extraction of DNA using
commercially available kits according to the manufacturer’s
instructions. Genomic DNA samples then underwent whole
genome amplification through either Primer Extension
Pre-amplification (PEP; Zhang et al., 1992) or Multiple Dis-
placement Amplification (MDA; Gonzalez et al., 2005),
before genotyping on a SequenomMass Array genotyping
platform (Ross et al., 1998). Details of the malaria candidate
polymorphisms genotyped, including the frequencies of
major alleles (“wild type alleles” that are dominant and most
frequent) and minor alleles (“mutant alleles” that are less
dominant and rare), are shown in Table S1.
Statistical analysis
All statistical analysis was performed using STATA (ver-
sion 11; Stata Corp, College Station, Texas, U.S.A.). Qual-
ity control procedures were applied to the genotype data
across both individuals and polymorphisms. For example,
polymorphisms with >10% genotypes missing duplicated
records and individuals with excessive missing genotypes
(>10%) were removed. We did not exclude polymorphisms
on the basis of Hardy-Weinberg equilibrium deviation
because both cases and controls were children admitted to
hospital.
Logistic regression models were used to measure poly-
morphism’s association with MAS or complex MAS (odds
ratios). The model could not run the associations for pure
focal seizures in all sites and pure prolonged seizures in
Muheza because of lack of power due to small numbers.
Models included the polymorphism of interest assuming
several related genotypic mechanisms (additive, dominant,
recessive, heterozygous advantage) and general models
(mutant homozygous and heterozygous gene against wild
homozygous gene). Based on an a priori assumption of
potentially confounding effects of country ethnic groups in
each site (accounts for between site differences), age, sex,
and adverse perinatal events (defined as delay in breathing,
crying and breastfeeding after birth) on the genetic suscepti-
bility for seizures in malaria, we adjusted for these factors
in the genotypic logistic regression models. We report the
minimum p-value from the correlated genotypic tests or
models. However, significant models with very large odds
ratios (>100) were not reported as this could have intro-
duced sparse-data bias due to infrequent genes in some cate-
gories.
Pooled estimates for genotypic tests were computed by
performing a logistic regression on combined raw data
across the four sites. We chose the raw data method after
establishing that its findings were similar to the individual
site estimates combined using the meta-analysis method
that utilizes both fixed effects (inverse-variance weighting)
and random effects models (where heterogeneity across the
sites is evident; DerSimonian & Laird, 1986). Meta-analysis
was used to compute Cochran’s Q statistic for estimating
genotypic tests’ heterogeneity across the sites.
Table 1. Case definition characterizing the phenotypes
ofmalaria-associated seizures
Category
of seizures Case definition characterizing the seizure phenotype
Repetitive
seizures
Two or more seizures within 24 h during the same illness
Prolonged
seizures
Seizures lasting  15 min and documented by a clinician or
a nurse
Convulsing on admission and does not stop after first dose
of diazepam
Use of phenytoin or phenobarbital to stop uncontrolled
seizures
Parental history suggesting of seizures lasting  15 min,
for example, a child convulsing all way to the hospital for
those living more than a kilometer away, seizures lasting
more than the period of boiling a pot of maize, milking a
dairy cow, or lasting more than the news broadcast on
the radio
Focal
seizures
Convulsions localized to or starting from one part of the
body
Rolling of eye, cycling movements, or twitching of mouth
localized to one body side
Lateralized asymmetric body weakness postictally (Todd’s
paralysis)
Motor deficits of the limbs of one side postseizure event
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Because performing multiple statistical tests leads to
inflation in the occurrence of false positives, we adjusted for
multiple testing using a permutation approach that
accounted for correlation between markers and tests (Gao
et al., 2008). The permutation approach was preferred to
Bonferroni correction because the polymorphisms in this
analysis were dependent on each other. A derived p-value of
0.009 was estimated to be significant for all genotypic tests,
and was based on both permutation adjustment (Gao et al.,
2008) and authors’ judgment that it was neither too liberal
to include false-positive nor too conservative to exclude
true-positive associations (Fig. S1).
All DNA samples were collected and genotyped after
approval was provided by the relevant research ethics com-
mittees and written informed consent was provided by the
participants.
Results
The distribution of phenotypes of MAS
Of the 2,095 cases of MAS across the sites, and the pro-
portion of complex MAS pooled from across the sites was
70.7%. Blantyre and Kilifi had the highest proportion of
complex MAS (543 [70.5%] and 652 [70.4%], respectively;
Fig. 1).
Focal MAS occurred in 306 children (14.6%) overall, and
the proportion was highest in Blantyre (143 [18.6%];
Fig. 1). Prolonged MAS occurred in 579 children (27.6%)
overall, and the proportion was highest (94 [37.6%]) in
Kumasi. Repetitive seizures occurred in 1,239 (59.1%) chil-
dren overall, and the proportion was highest in Blantyre
(501 [65.1%]).
The proportion of complex MAS that was focal was high-
est in Muheza (31 [29.0%]) (Fig. 1). The proportion of com-
plex MAS that was prolonged was highest in Kumasi 94
(63.5%). The proportion of complex MAS that was repeti-
tive was highest in Blantyre 501 (92.3%). There was consid-
erable overlap between the complex phenotypes and the
distribution differed across the sites (Fig. 1).
The proportion of cases who met the WHO definition of
cerebral malaria (also referred to as “MAS with coma” was
1,267/2,095 [60.5%] for all sites, 713/770 [92.6%] for Blan-
tyre, 410/900 [45.6%] for Kilifi, 73/250 [29.2%] for Kum-
asi, and 71/175 [40.6%] for Muheza). The proportion of
cases with a previous history of seizures was 320/2,095
(15.3%) for all sites, 190/770 (24.7%) for Blantyre, 100/900
(11.1%) for Kilifi, 29/250 (11.6%) for Kumasi, and 1/175
(0.6%) for Moshi.
Minor allele frequencies and genotypic tests
The minor allele frequencies for the polymorphisms con-
sidered in the final analysis are summarized in Table S1.
Generally there was little heterogeneity of minor allele
frequencies between cases and controls either within or
between each site. Following filtering of the single nucleo-
tide polymorphisms (SNPs) as described in Methods, analy-
sis for association with MAS was undertaken using several
genetic polymorphisms (Tables 2–7). Results for SNPs
where the p-values from the analysis were <0.009 (to allow
for multiple testing [see Methods]) were identified and are
shown with the data from across all sites.
Polymorphisms associated with all MAS
All-MAS encompasses all MAS phenotypes and two
genes were significantly associated with all-MAS in at least
two sites, IL10-rs1800896 in Blantyre (odds ratio
[OR] = 0.37 [95% confidence interval (CI), 0.18–0.74],
p = 0.00531, recessive model) and Kumasi (OR = 0.53
[95% CI, 0.33–0.84], p = 0.00739, heterozygous model)
and epidermal growth factor module-containing mucin-like
hormone receptor (EMR)1-rs373533 in Blantyre (4.96
[95% CI, 1.78–13.81], p = 0.00219, additive model) and
Kumasi (OR = 0.52 [95%CI, 0.33–0.81], p = 0.00360, het-
erozygous model). A second SNP (rs461645) in EMR1 was
also significant in Blantyre and Kumasi due to high linkage
disequilibriumwith EMR1-rs373533 in all the ethnic groups
(r2 > 0.9, data not shown). Others shown in Table 2 were
significantly associated with MAS in one site only.
Most polymorphisms were not significant in analysis
pooled across-site analysis except for IL10-rs3024500
(OR = 1.36 [95% CI, 1.08–1.71], p = 0.00651, general
model) and IL-17 receptor E-rs708567 (OR = 0.78 [95%
CI, 0.65–0.94], p = 0.00709, recessive model). We also
looked for associations in the sub-phenotypes of MAS to
reduce heterogeneity of the phenotype, reported below,
although there would be some loss of power in the sample
sizes. Meta-analysis of association estimates of IL10-
Figure 1.
Proportion of complex seizures in each site. A: Blantyre, Malawi
(N = 543); B: Kilifi, Kenya (N = 652); C: Kumasi, Ghana
(N = 148); D: Muheza, Tanzania (N = 107). Percentages were
computed using denominators as numbers for each site.
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The Genetic Risk of Acute Seizures
rs1800896 in the all MAS phenotype showed that there was
considerable heterogeneity across the sites (68.7% [95% CI
34.8–93.3%]).
Polymorphisms associated with all-complexMAS
This phenotype comprises the prolonged, focal, and
repetitive phenotypes that together define the majority of
the malaria-associated seizures.We analyzed them together,
since they have some degree of overlap (Fig. 1). Several
genes showed a significant association in at least one site
(Table 3), two of which were significant in all-MAS above,
namely IL10-rs1800896 (OR = 0.43 [95% CI, 0.24–0.75],
p = 0.00309, heterozygous model) in Kumasi and EMR1-
rs373533 in Blantyre (OR = 4.43 [95% CI, 1.47–13.34],
p = 0.00813, heterozygous model) and Kumasi (OR = 0.38
[95% CI, 0.23–0.65], p = 0.00033, heterozygous model).
None of these SNPs were associated with complex MAS in
a pooled analysis.
Polymorphisms associated with focal-MAS, prolonged-
MAS, and repetitive-MAS
Several polymorphisms, none of which appeared in MAS
and complex MAS, were significantly associated with focal
MAS, particularly IL-20 receptor A-rs1555498 (OR = 3.86
[95% CI, 1.67–8.97], p = 0.00158, recessive model) in
Moshi and CD36-rs3211938 (OR = 10.16 [95% CI, 1.79–
57.83], p = 0.00894, recessive model) for Kumasi. How-
ever, there was no significant association with focal MAS in
a pooled analysis across the sites.
Three polymorphisms that appeared significant in MAS
and/or complex MAS were associated with prolonged MAS
(Tables 3 and 4), EMR1-rs461645 (OR = 0.41 [95% CI,
0.23–0.74], p = 0.00336, heterozygous model) in Kumasi
and CR1-rs1704660 (OR = 3.92 [95% CI, 1.71–8.99],
p = 0.00121, general model) and IL17RE-rs708567
(OR = 0.55 [95% CI, 0.35–0.86], p = 0.00917, additive
model) in Kilifi. Only CRI-rs1704660 from these two poly-
morphisms was significant in a pooled analysis across the
sites (Table 5).
Two polymorphisms identified as significant in MAS,
complex MAS, or prolonged MAS (Tables 3 and 4), were
associated with repetitive MAS, EMRI-rs373533 in Blan-
tyre (OR = 5.73 [95% CI, 1.67–19.65], p = 0.00545, gen-
eral model) and Kumasi (OR = 0.27 [95% CI, 0.14–0.50],
p = 0.00003, heterozygous model) and CR1-rs17047660
(OR = 3.04 [95% CI, 1.51–6.12], p = 0.00180, recessive
model) in Kilifi. Of these two polymorphisms only CR1-
rs17047660 (OR = 1.97 [95% CI, 1.22–3.22], p = 0.00547,
recessive model) was associated with repetitive MAS in the
pooled analysis, and others were as well (Table 6).
Polymorphisms association withMASwith coma/
cerebral malaria
Two polymorphisms associated with most of the above
phenotypes (Tables 2–6) were also significant for MAS
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with coma, EMRI-rs373533 in Blantyre (OR = 4.58
[95% CI, 1.62–12.93], p = 0.00405, additive model) and
Kumasi (OR = 0.26 [95% CI, 0.13–0.53], p = 0.00019,
dominant model) and CR1-rs17047660 in Kilifi
(OR = 3.47 [95% CI, 1.51–7.99], p = 0.00341, general
model), Kilifi and Moshi (OR = 0.25 [95% CI, 0.11–
0.60], p = 0.00177, additive model). CD40-rs1126935
too was associated with MAS with coma in more than
one site (Table 7).
Discussion
This is the first study to investigate the effect of candidate
genes for malaria infection on the risk of acute seizures
across multiple sites in Africa. Using established definitions
for seizure phenotypes (Table 1), our data show that a sig-
nificant proportion (>70%) of children admitted to hospitals
in sub-Saharan Africa with severe malaria exhibit seizures
with complex features (prolonged, focal, or repetitive), but
the proportions of the different phenotypes vary between
sites. A number of different polymorphisms (including the
X-chromosome) were associated with the risk of the main
phenotypes of MAS at each site, and in a pooled analysis.
Polymorphisms of four genes were identified as significant
in most of the subgroups and sites (CR1-rs1704660, IL10-
rs1800896, and EMR1-rs373533/rs461645 and CD40-
rs3092945 [females]), although only CR1 showed an overall
significant association across the sites in the prolonged and
repetitive MAS phenotypes. Other polymorphisms did show
positive association but mostly for one phenotype and site
(Table 3). Of the positive association polymorphisms sev-
eral are thought to code for molecules that could have a
putative role in the pathogenesis of seizures in falciparum
malaria.
The classification of seizures is largely based on pheno-
types found in febrile seizures (Baram & Shinnar, 2002),
but some cases may have been misclassified, since general-
ized seizures may have had a focal origin with rapid second-
ary generalization (Gwer et al., 2012). We were not able to
determine relatedness of the study participants, which may
affect the associations, but adjusting for ethnicity did in part
account for this. Electroencephalography and neuroimaging
were not routinely performed at the time of the study due to
logistic reasons. The strength of our study lies in the large
sample size from combining studies across four countries,
which allowed us to use a control group that comprised the
severe malaria cases without seizures, thus ensuring that
any associations identified represent the risk of developing
acute seizures in malaria. The genotypic tests p-values are
reported as they were generated from the analyzing soft-
ware, so are easier to interpret.
Polymorphisms demonstrated heterogeneities in associ-
ations with MAS across the sites. These heterogeneities
may be ascribed to sample size differences and the result-
ing power (Muheza had the smallest samples), possible
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differences in documenting the three phenotypes of com-
plex MAS, haplotypic (polymorphisms on one or several
loci that may be associated) differences between popula-
tions, and/or the effects of population structure. We tried
to minimize the latter by adjusting for ethnicity within
sites. Some of the heterogeneous associations in the sites
may be due to linkage disequilibrium. Because we
adjusted for multiple testing, such site-specific associa-
tions could be due to strong linkage disequilibrium with
actual causal polymorphisms not investigated in this
study. The finding that a gene was protective in one site
and increased risk in another can be explained by the dif-
ferent inheritance models in the affected sites, or could
suggest that the associations are related to a gene region
rather than the effect of the particular polymorphism.
In these associations, we studied polymorphisms that were
genotyped as part of MalariaGEN consortium project (Malar-
iaGEN, 2008), and could not investigate some polymor-
phisms associated with febrile seizures such as the six
susceptibility febrile seizure loci (FEB)1–6, voltage-gated
sodium channel genes (SCN1A, SCN1B, or SCN2A), c-amino-
butyric acids genes (GABA(A) or GABRG2) (Nakayama
& Arinami, 2006). We did, however, include poly-
morphisms of the interleukin family (IL-1A, 1L-1B, 1L-4,
1L-20RA), some of which have been previously investi-
gated in febrile seizures studies (Tsai, 1987; Virta et al.,
2002; Kira et al., 2005; Ishizaki et al., 2009).
Some polymorphisms had stronger associations with
acute seizures with complex phenotypes, suggesting that
these three phenotypes may provide insights into the epile-
ptogenesis of malaria. The finding that specific polymor-
phisms were replicated across the different complex
phenotypes supports the role of these genes in the epilepto-
genesis of malaria. The complex phenotypes are particularly
associated with malaria (Kariuki et al., 2011) and are also
important risk factors for development of epilepsy follow-
ing severe malaria (Birbeck et al., 2010). Those polymor-
phisms that are found in more than one site are likely to be
linked to genes that may play a significant role in the patho-
genesis of acute seizures in these children.
The biologic functions of some polymorphisms have not
been fully investigated, and can only be speculated. EMR1
is sometimes elevated in placental malaria (Muehlenbachs
et al., 2007; Sevastianova et al., 2008), which is character-
ized by sequestration of parasites, similar to that found in
the brain. EMR1 is a membrane receptor that also activates
G protein receptor subunit alpha (GNAS) (Auburn et al.,
2008), whose subclass C receptors bind glutamate and
GABA, the two important neurotransmitters of epileptogen-
esis. GNAS did not reach the 0.009 significance level in this
study but reached the 0.05 level. In addition, EMR1 is the
human homologue of F4/80 in mice that defines macro-
phages, whose elevation in malaria infection precedes leu-
cocyte sequestration into the brain (Wozencraft et al.,
1984).
Many of the polymorphisms genotyped in this study
have previous published associations with severe malaria,
and we have analyzed them in the context of association
with seizures. CR1 is postulated to be involved in the adhe-
sion of P. falciparum infected erythrocytes to uninfected
erythrocytes (rosetting; Nagayasu et al., 2001; Idro et al.,
2005) and is therefore thought to play a role in the patho-
genesis of seizures in severe malaria. Polymorphisms of
the ABO blood system are associated with rosetting of ery-
throcytes among people of blood types A and B (Cserti &
Dzik, 2007), resulting in impaired tissue perfusion that
could increase the risk for seizures. Similarly, the associa-
tion between ICAM1 polymorphisms seizures with severe
malaria (Kun et al., 1999) could be explained by the bind-
ing of ICAM1 to P. falciparum–infected erythrocytes onto
brain microvasculature (Berendt et al., 1992; Kun et al.,
1999) causing sequestration. CD36 facilitates this seques-
tration (Cserti & Dzik, 2007). Interleukins are usually
increased in falciparum malaria infections, and may
directly precipitate seizures because they are inflammatory
and pyrogenic in nature (Haysa et al., 1999; Chaisavanee-
yakorn et al., 2003; Wilson et al., 2005). G6PD enhances
parasite clearance by phagocytosis, a process that can
culminate in release of inflammatory molecules often asso-
ciated with seizures (Sabeti et al., 2002; Wilson et al.,
2005). Activation of microglial CD40 results in inflamma-
tion-induced seizures (Sun et al., 2008) and underpins the
association between this polymorphism and MAS in coma/
cerebral malaria.
Our findings have demonstrated that children admitted
with falciparum malaria may have a genetic predisposition
to acute seizures, but the polymorphisms associated with
seizures in malaria vary with the phenotype and sites across
Africa. These polymorphisms were particularly associated
with the three complex phenotypes of MAS, which could
also be important in epileptogenesis of severe malaria. Stud-
ies from other malaria-endemic settings are required to
confirm these findings, and genome-wide association stud-
ies are required to study if other seizures-specific genes
determine the risk of acute seizures.
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